Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo

Summary

Using gain-of-function factor IX (FIX) for replacement therapy for haemophilia B (HB) is an attractive strategy. We previously reported a high-activity FIX, FIX-Triple (FIX-V86A/E277A/R338A) as a good substitute for FIX-WT (wild-type) in protein replacement therapy, gene therapy, and cell therapy. Here we generated a new recombinant FIXTripleL (FIX-V86A/E277A/R338L) by replacing the alanine at residue 338 of FIX-Triple with leucine as in FIX-Padua (FIX-R338L). Purified FIX-TripleL exhibited 22-fold higher specific clotting activity and 15-fold increased binding affinity to activated FVIII compared to FIXWT. FIX-TripleL increased the therapeutic potential of FIX-Triple by nearly 100% as demonstrated with calibrated automated thrombogram and thromboelastography. FIX-TripleL demonstrated a normal clearance rate in HB mice. The clotting activity of FIX-TripleL was consistently 2- to 3-fold higher in these mice than that of FIX-Triple or FIXR338L. Gene delivery of adeno-associated virus (AAV) in HB mice showed that FIX-TripleL had 15-fold higher specific clotting activity than FIX-WT, and this activity was significantly better than FIX-Triple (10-fold) or FIX-R338L (6-fold). At a lower viral dose, FIX-TripleL improved FIX activity from sub-therapeutic to therapeutic levels. Under physiological conditions, no signs of adverse thrombotic events were observed in long-term AAV-FIX-treated C57Bl/6 mice. Hepatocellular adenomas were observed in the high- but not the medium- or the lowdose AAV-treated mice expressing FIX-WT or FIX-Triple, indicating the advantages of using hyperfunctional FIX variants to reduce viral doses while maintaining therapeutic clotting activity. Thus, incorporation of the FIX Padua mutation significantly improves the clotting function of FIX-Triple so as to optimise protein replacement therapy and gene therapy.

Keywords

Coagulation factors - haemophilia therapy - animal models

• References

• 1 Pipe S. Consideration in hemophilia therapy selection. Semin Hematol 2006; 43: S23-27.
• 2 Nathwani AC, Tuddenham EG, Rangarajan S. et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-2365.
• 3 Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008; 15: 808-816.
• 4 Manno CS, Pierce GF, Arruda VR. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
• 5 Donsante A, Miller DG, Li Y. et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007; 317: 477.
• 6 Herzog RW, Davidoff AM, Markusic DM. et al. AAV vector biology in primates: finding the missing link?. Mol Ther 2011; 19: 1923-1924.
• 7 Schuettrumpf J, Herzog RW, Schlachterman A. et al. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 2005; 105: 2316-2323.
• 8 Lin CN, Kao CY, Miao CH. et al. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. J Thromb Haemost 2010; 08: 1773-1783.
• 9 Chang J, Jin J, Lollar P. et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem 1998; 273: 12089-12094.
• 10 Wu YM, Kao CY, Huang YJ. et al. Genetic modification of donor hepatocytes improves therapeutic efficacy for hemophilia B in mice. Cell Transplant 2010; 19: 1169-1180.
• 11 Kao CY, Lin CN, Yu IS. et al. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis. Thromb Haemost 2010; 104: 355-365.
• 12 Simioni P, Tormene D, Tognin G. et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361: 1671-1675.
• 13 Mazetto MBde, Orsi FL, Siqueira LH. et al. Prevalence of Factor IX-R338L (Factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels. Thromb Res 2010; 126: e165.
• 14 Koenderman JS, Bertina RM, Reitsma PH. et al. Factor IX-R338L (Factor IX Padua) screening in a Dutch population of sibpairs with early onset venous thromboembolism. Thromb Res 2011; 128: 603.
• 15 Cantore A, Nair N, Della PValle. et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood 2012; 120: 4517-4520.
• 16 Finn JD, Nichols TC, Svoronos N. et al. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood 2012; 120: 4521-4523.
• 17 Jin DY, Zhang TP, Gui T. et al. Creation of a mouse expressing defective human factor IX. Blood 2004; 104: 1733-1739.
• 18 Chang YJ, Wu HL, Hamaguchi N. et al. Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis. Residues Asn(89)-Gly(93) are critical for binding factor VIIIa. J Biol Chem 2002; 277: 25393-25399.
• 19 Kao CY, Lin CN, Yang YL. et al. Characterisation of factor IX with a glycine-tovaline missense mutation at residue 190 in a patient with severe haemophilia B. Thromb Haemost 2011; 105: 616-626.
• 20 Griffith MJ, Breitkreutz L, Trapp H. et al. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill. J Clin Invest 1985; 75: 4-10.
• 21 Bevington PR, Robinson DK. Data reduction and error analysis for the physical sciences. 2nd ed.. McGraw-Hill; 1992
• 22 Straume M, Johnson ML. Analysis of residuals: criteria for determining goodness-of-fit. Methods Enzymol 1992; 210: 87-105.
• 23 Segel IH. Enzyme kinetics : behavior and analysis of rapid equilibrium and steady state enzyme systems. Wiley; 1975
• 24 Lin HF, Maeda N, Smithies O. et al. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-3966.
• 25 Haemoscope. TEG 5000 User Manual. Haemoscope Corporation; 2008
• 26 Cohen E, Caprini J, Zuckerman L. et al. Evaluation of three methods used to identify accelerated coagulability. Thromb Res 1977; 10: 587-604.
• 27 Caprini JA, Zuckerman L, Cohen E. et al. The identification of accelerated coagulability. Thromb Res 1976; 09: 167-180.
• 28 Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
• 29 Miao CH, Thompson AR, Loeb K. et al. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 2001; 03: 947-957.
• 30 Chen CY, Tsai MS, Lin CY. et al. Rescue of the genetically engineered Cul4b mutant mouse as a potential model for human X-linked mental retardation. Hum Mol Genet 2012; 21: 4270-4285.
• 31 Chang JY, Monroe DM, Stafford DW. et al. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest 1997; 100: 886-892.
• 32 Hopfner KP, Brandstetter H, Karcher A. et al. Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants. EMBO J 1997; 16: 6626-6635.
• 33 Brunetti-Pierri N, Grove NC, Zuo Y. et al. Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Hum Gene Ther 2009; 20: 479-485.
• 34 Shapiro AD, Ragni MV, Valentino LA. et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-672.
• 35 Peters RT, Low SC, Kamphaus GD. et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 2057-2064.
• 36 Metzner HJ, Weimer T, Kronthaler U. et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102: 634-644.
• 37 Ostergaard H, Bjelke JR, Hansen L. et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333-2341.
• 38 Kolkman JA, Lenting PJ, Mertens K. Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity. Biochem J 1999; 339: 217-221.
• 39 Mathur A, Bajaj SP. Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa. J Biol Chem 1999; 274: 18477-18486.
• 40 Manno CS, Chew AJ, Hutchison S. et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
• 41 Buchlis G, Podsakoff GM, Radu A. et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012; 119: 3038-3041.
• 42 Arruda VR, Stedman HH, Nichols TC. et al. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 2005; 105: 3458-3464.
• 43 Arruda VR, Stedman HH, Haurigot V. et al. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood 2010; 115: 4678-4688.
• 44 Fuchs HE, Trapp HG, Griffith MJ. et al. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J Clin Invest 1984; 73: 1696-1703.
• 45 Lozier JN, Tayebi N, Zhang P. Mapping of genes that control the antibody response to human factor IX in mice. Blood 2005; 105: 1029-1035.
• 46 Nakai H, Montini E, Fuess S. et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 2003; 34: 297-302.
• 47 Li H, Malani N, Hamilton SR. et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood 2011; 117: 3311-3319.
• 48 Davidoff AM, Gray JT, Ng CY. et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005; 11: 875-888.
• 49 Nathwani AC, Gray JT, Ng CY. et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006; 107: 2653-2661.